New Maryland Governor Endorses Smoking Ban in All Public Places

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 2
Volume 4
Issue 2

ANNAPOLIS, Md--Last year, a Maryland court placed on indefinite hold a proposed ban on smoking in all public places, including bars, restaurants, and every workplace in the state.

ANNAPOLIS, Md--Last year, a Maryland court placed on indefinitehold a proposed ban on smoking in all public places, includingbars, restaurants, and every workplace in the state.

That ban may see new life, however. Governor-elect Parris Glendenninghas endorsed the main provisions of the proposed sanctions exceptfor hotels and very small restaurants and taverns, where sucha ban might be unduly economically burdensome. The ban would beone of the first of its kind in the nation and is opposed by varioustobacco industry and business groups.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content